Platinum-Based Chemotherapy for Advanced-Stage Serous Ovarian Carcinoma of Low Malignant Potential

By Barakat R.R.   Benjamin I.   Lewis Jr. J.L.   Saigo P.E.   Curtin J.P.   Hoskins W.J.  

Gynecologic Oncology, Vol. 59, Iss. 3, 1995-12 ,pp. : 390-393

Academic Press

Access to resources Recommend Favorite

TP53 Mutation in Ovarian Carcinoma

By Murphy M.   McManus D.T.   Toner P.G.   Russell S.E.H.  

European Journal of Cancer, Vol. 33, Iss. 8, 1997-07 ,pp. : 1281-1283

Elsevier

Access to resources Recommend Favorite

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

By                

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

By Foedermayr Mathilde   Sebesta Miriam   Rudas Margaretha   Berghoff Anna   Promberger Regina   Preusser Matthias   Dubsky Peter   Fitzal Florian   Gnant Michael   Steger Guenther   Weltermann Ansgar   Zielinski Christoph   Zach Otto   Bartsch Rupert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 771-778

Springer Publishing Company

Access to resources Recommend Favorite

Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma – diagnostic and prognostic implications

By Berner Heidi   Davidson Ben   Berner Aasmund   Risberg Bjørn   Kristensen Gunnar   Trope Claes   Van de Putte Gregg   Nesland Jahn  

Clinical and Experimental Metastasis, Vol. 18, Iss. 2, 2000-03 ,pp. : 197-202

Springer Publishing Company

Access to resources Recommend Favorite